| Dr. Hitto Kaufmann is a biopharma leader with over 20 years of experience in research, development and manufacturing with a track record in development of more than 100 biological therapeutic entities. Currently he is Chief Scientific Officer at Pieris Pharmaceuticals leading an integrated protein therapeutic platform from discovery to manufacturing. He also serves as site-head of the main R&D site in Munich. Prior to joining Pieris, Dr. Kaufmann spent five years at Sanofi, where he held several executive positions in Industrial Affairs and R&D. During his time there, he led efforts to build a strong cross-divisional end-to-end technology platform for Sanofi Biologics that included several strategic deals. He also went on to head Global Biopharmaceutics Development, managing over 700 employees across three sites tasked with drug substance and drug product technical development, analytics, clinical supply and release. Finally, he oversaw key strategic projects on digitalization and data sciences, as well as the integration of the Ablynx platform into the Sanofi network. Before his tenure at Sanofi, Dr. Kaufmann spent more than a decade at Boehringer Ingelheim, most recently in the Biopharmaceuticals division as Vice President, Process Science. He began his career as a Research Scientist at the Walter and Eliza Hall Institute in Melbourne. Dr. Kaufmann received his Ph.D. in Natural Science, focusing on cell culture technology, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in biotechnology from the Technical University of Braunschweig and the Scripps Research Institute. He is a member of the Scientific Advisory Board of IBET (Instituto de Biologico Experimental e Technologia, Portugal) and the National Biologic Facility Denmark and has authored over 25 peer-reviewed publications. |
